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Abstract
As patients begin to receive more oral chemotherapies in the place of the traditional
parenteral therapies, the responsibility for treatment falls on the shoulders of patients and
their caregivers. The responsibility for the “five rights” of medication administration,
which include the- right drug, right dose, right time, right route, and right patient are
being transferred to patients and care givers. This places patients at risk for medications
errors. Patients and care providers assume responsibility for medication administration,
often with little or no healthcare education. As the number of patients being prescribed
chemotherapies continues to increase, an emphasis on education as well as adherence to
therapy should be emphasized. Multiple barriers exist, that negatively affect a people’s
ability to adhere with prescribed treatment. A systematic review was conducted to
identify the most prevalent barriers to nonadherence in this patient population. The
Preferred Reporting Items for Systematic Reviews (PRISMA) checklist and flowchart
were utilized to extrapolate, analyze, and synthesize the date. Common themes were
identified and organized into three main categories: patient-related factors, system-related
factors, and nurse and provider-related factors. The most prevalent were analyzed in
further detail which revealed there were multi-factorial causes of nonadherence to oral
chemotherapies. Under the patient-related heading, adverse effects and toxicities as well
as forgetfulness were seen most commonly in the literature. Within the theme of systemrelated both regimen complexity and financial causes were found, whereas under nurse
and provider-related patient education and frequency and length of follow up were most
common. The advanced practice nurse (APN) is in the prime position to help counter-act
these barriers to adherence. This systematic review served to help identify common
causes of nonadherence to patients’ oral chemotherapeutic agents as prescribed.
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ORAL CHEMOTHERAPY, A TOUGH PILL TO SWALLOW:
A SYSTEMATIC REVIEW
Background/Statement of the Problem
It is estimated that approximately 25-30% of all chemotherapeutic agents
currently undergoing clinical trials are now by oral route of administration, and this
number is expected to grow (Tipton, 2015). While oral therapies are often more
convenient for patients, there are several important factors regarding adherence or
compliance with treatment that should be taken into consideration. One exploratory study
found that the primary population being given oral chemotherapies were older adults, had
several comorbid conditions, and had advanced stage cancer (Given et al., 2015). Another
study found similar results: subjects were primarily: women, had on average 2.8
comorbidities, were diagnosed with late stage cancer, and had no caregivers at home
(Wong, Bounthavong, Nguyen, Bechtoldt, & Hernandez, 2014). All of these factors
increase the potential for non-adherence to oral chemotherapies placing patients at risk
for poorer outcomes and higher mortalities. It is important to acknowledge these and
other barriers to compliance with oral chemotherapy regimens so that healthcare
providers are better able to mitigate them. These include such factors as belief in efficacy,
psychological factors, comorbidities, complicated regimen, communication, and
education as supported in the following literature review.
Chemotherapy administration is moving out of the infusion centers and hospitals,
where providers are readily available to monitor and assess them, and into their homes.
While this change increases patient’s autonomy, freedom, and potentially decreasing
hospitalizations, exposure to potential infections, and disruptions to patients’ lives, it also
comes with a tradeoff. Patients are seen by healthcare staff less often and are at higher
risk for adverse reactions, under or over-adherence, and undertreated side effects.
This issue is particularly relevant to nurses for several reasons as nonadherence is
a concept that is very familiar and pertinent to nursing. Nurses are often the staff dealing
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with the fallout of nonadherence, providing education, advocating for patients, assisting
with obtaining financial resources, attending to side effects and worsening disease, and
more. This systematic review will explore issues surrounding nonadherence to oral
chemotherapy agents and contributing factors in order to change nursing practice around
these medications. Nurses have the power to positively affect patient outcomes as they
generally have more contact with patients and their caregivers.
The review of the literature will be discussed in the next section.
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Literature Review
Adherence and Nonadherence Defined
The World Health Organization (WHO) defines adherence as “the extent to which
a person’s behavior-taking medication, following a diet, and/or executing lifestyle
changes corresponds with agreed recommendations from a healthcare provider.”(World
Health Organization, 2003, p. 17). The NICE guidelines define adherence similarly as the
level to which the patient’s medication taking practices match the recommendations of
the physician. This definition however, makes the assumption that there is a mutual
agreement on the part of both the patient and the physician prescribing (Mantri, 2014).
Adherence contrasts with the previously used term compliance in several ways.
First, the term adherence denotes a mutual agreement with both patient and provider,
while the term compliance has the connotation of a passive relationship where the patient
is expected to unquestioningly obey orders and take medications as prescribed (Mitchell,
2014). Compliance in today’s healthcare system is a term that is much less commonly
used due to its outdated application in a paternalistic system. It is still commonly used
however as it applies to the psychiatric population as at times patients who are
incompetent are treated without the direct consent of the patient themselves for their
safety (Vuckovich, 2010). Vuckovich refers in her research specifically to those patients
who are in a state of psychosis, but acknowledges that forced compliance in patients who
are incompetent is seen in other populations as well, such as those with forms of
dementia.
A patient is considered non-adherent if they do not take their medications as
prescribed due to missing doses, taking too many doses, taking medications at the wrong
time, or at the wrong dosage (World Health Organization, 2003). Mantri (2014) defines
nonadherence as when a patient does not take prescribed medications exactly as ordered
and may be partial or total, intentional or unintentional, and continuous or intermittent in
nature. She further stated that levels of nonadherence have been reported at 20-70%, but
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attributes these statistics to varying definitions among researchers, study methods, and
populations. Mitchell (2014) similarly reported nonadherence rates as ranging from 2060%, with the highest concentration of nonadherence occurring with patients with
chronic conditions.
There are several types of nonadherence to consider (Gellad, Grenard,
&McGlynn, 2009). One type is called “non-fulfillment” when a prescriber orders a
particular medication, but the patient does not have the prescriptions filled. It further
extends to patients who do have the medication filled, but fail to pick it up and may be
referred to as “primary nonadherence”. Another type includes “non-persistence” and
occurs when a patient autonomously decides to cease taking their prescribed medications
without the direction of a physician. Studies have found that this generally occurs within
six months of initiating a medication regimen. A third type of nonadherence includes
“non-conforming” and includes when a patient takes medication in a way that is not
ordered by their prescriber. This may mean that a patient takes too few or too many
doses, takes it at the wrong time, wrong dose, or misses doses. As with many aspects of
healthcare, nonadherence with medication and the severity of repercussions associated
with it vary based on the type of medication. Taking antibiotics inappropriately can lead
to severe health consequences such as drug resistant bacteria or recurrent infection, while
missing a dose of a thyroid medication or vitamin may not have such severe concerns
(Gellad et al.).
Nonadherence is not a new phenomenon and certainly not specific to the
hematology/oncology population. The World Health Organization (WHO, 2013) reported
that adherence within the hematology/oncology population can be as low as 20%. Issues
related to adherence have been heavily studied in HIV patients and are being more
thoroughly examined in other patient populations (WHO). As patients with all types of
diseases and conditions are living longer and diagnoses that at one time were a death
sentence are now a chronic disease, the importance of adherence is crucial. Nonadherence
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is closely linked with poor patient outcomes, increased resistance to therapies, toxicities,
adverse events, and side effects and also significantly increases the amount of healthcare
dollars being spent every year (WHO). The WHO also reported that nonadherence has
the potential to increase healthcare resources utilized, increase the amount of disability,
have psychological implications, and substantially decrease quality of life of the patient.

Barriers to Adherence
Merriam-Webster defines barrier as “something immaterial that impedes or
separates; an obstacle” as well as “something that makes it difficult for people to
understand each other” (http://www.merriam-webster.com/dictionary/barrier). The
application of this term is without exact consensus in the healthcare community literature,
as the focus tends to be on defining “adherence”. Barriers can be further defined as either
experienced or perceived as it relates to medication adherence (Duran, George, & Norris,
2014). The broad umbrella categories of barriers to adherence include socioeconomic,
healthcare systems, disease, treatment regimen, and patient related. Within these
categories fall more specific barriers such as language, homelessness, lack of insurance,
poor communication and follow up with physicians, degree of severity of symptoms,
regimen complexity, side effects, physical factors,
psychological/behavioral/developmental factors, and more ("OncoLink," 2014).
The importance of understanding barriers, both actual and perceived, is crucial in
order to develop strategies and interventions to help patients cope with or avoid barriers
(Oncology Nursing Society, 2009). Practitioners have utilized several different tools to
help patients increase adherence. One such tool is a calendar which depicts what
medications a patient needs to take, at what dose, and when to take it. Additionally, many
drug manufacturers provide financial resources to patients who fall below a certain
income level. This may mean that a patient may qualify for either partial or complete cost
assistance and thereby decreasing many financial barriers. Patient education is another
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powerful way to alleviate barriers to adherence and may include several different key
pieces of information. Education of patients should extend to family, friends, and
caregivers whenever possible and should include; side effects, how and when to take their
medication, written information in the patient’s primary language, and places they can
obtain additional quality information according the ONS (2009).
Nonadherence and the General Patient Population
Minor changes within a patient’s environment can have a strong barrier effect on
adherence to oral medication. A study (DeBakker, Bouvy, Heerdink, Spreeuwenberg,
&Vervloet, 2013) performed in the Netherlands on 104 diabetic patients found that even
the day of the week and the time of day that a patient is instructed to take their
medications can greatly predict adherence. The authors in this study utilized a real time
medication monitoring system that recorded the date and time a patient self-administered
their medications. Adherence was seen to a greater degree (96%) Monday through
Thursday when ordered to be taken in the morning at. This is in stark contrast to those
medications patients take in the evening, where adherence dipped down to 33%,
particularly on Sunday evenings. There was a linear correlation seen with adherence that
was found to decrease each day of the week, starting on a Monday and ending with the
lowest adherence on Sunday. Patients were also noted to have more missed doses on
holidays in addition to weekends. The authors came to the conclusion that any
interruptions to a one’s daily routine ran the risk of decreasing adherence (DeBakker et
al.).
In a review of the literature (Duncan, 2015), complex regimens with multiple
daily dosing had lower rates of patient adherence in those with chronic obstructive
pulmonary disease (COPD). Patients who were prescribed inhalers that were to be used
multiple times within a 24 hour period had poor rates of adherence that tapered off the
longer they were on therapy. These patients had more complications associated with
exacerbations, had more hospitalizations, and took longer to recover. Recommendations
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were to increase self-management of all patients, providing additional teaching and
pertinent information as well as simplification of regimens when possible (Duncan).
Some forms of nonadherence are intentional, since some patients consciously
decide to stop taking their medications or to take them in a way other than prescribed.
Using Leventhal’s Common-Sense Model of Self-Regulation, Jackson et al. described six
factors that may play a crucial role in intentional nonadherence with geriatric patients.
These six aspects include: beliefs about their illness, the risks that they perceive can
occur from taking the medication, the potential benefits, the relationship between the
prescribing practitioner and the patient, both physical and mental illnesses, availability of
financial resources, and issues related to polypharmacy or complex regimens. One
important factor for healthcare providers to keep in mind is that there is overlap between
intentional and unintentional nonadherence. Patients who pose an increased risk for this
overlap are those elderly who are frail and/or socially isolated from others. Historically
speaking, those who are non-adherent, whether intentional or unintentional, have been
grouped together by healthcare professionals. Unintentional nonadherence is defined as
nonadherence that is not a conscious decision, versus intentional which is. The distinction
between the two is an important one to make because the interventions intended to
decrease nonadherence vary based on the underlying causes (Jackson, Mukhtar,
&Weinman, 2014).
Some patient populations have specific issues related to nonadherence such as
transplant patients. One would assume that after being given the gift of life via a new
organ, a patient would be very strictly adherent to prescribed anti-rejection therapies. In
one systematic review the authors found that as time post-transplant increases, patients
have less follow up, have their labs drawn less frequently, and become more nonadherent with treatments, thus leaving them vulnerable to rejection. This systematic
review focused on varying factors influencing nonadherence following transplantation of
a solid organ (Morrissey, Flynn, & Lin, 2007).The human cost of nonadherence with
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transplant patients is large and can lead to graft failure and either chronic or acute
rejection. Not only is this physically damaging and life threatening for patients, but also
spiritual, emotional, and psychological as well. According to Morrissey et al. (2007),
financially, it is costly due to increased hospitalizations, biopsies, more expensive antirejection medications, as well as possible need for additional transplant.
It is clear that nonadherence in all patient populations can decrease quality of life
(QOL) and increase healthcare dollars spent each year according to the previously
mentioned data. The importance of understanding the etiology of nonadherence is crucial
to decreasing or alleviating it so that patients can have better outcomes with their given
therapies. While each patient specific population has their own challenges, there is a
lesson to be learned from each that can be applied to another. By looking at adherence
among various patient populations, healthcare providers can extrapolate pertinent data
that can then be applied to other populations, including hematology/oncology.
Nonadherence and Patients with Comorbidities.
More often than not, patients with cancer diagnoses have comorbid conditions. In
a case study by Spoelstra (2015), a 52 year old woman with a diagnosis of chronic
lymphocytic leukemia (CLL) had a history of diabetes mellitus, chronic obstructive
pulmonary disease, asthma, urinary tracts infections (UTI), and depression. She was
prescribed ibrutinib for her CLL. She was subsequently diagnosed with a UTI and placed
on ciprofloxacin. This patient had severe adverse effects from a drug-drug interaction
between the two drugs which required medical interventions. This example demonstrates
how comorbidities increase the risk of adverse drug reactions, confusion related to
multiple medications, drug-drug interactions, ability to self-manage conditions, increased
pill burden, and may exacerbate pre-existing conditions (Spoelstra).
Disease and health factors play an important role in adherence along with other
factors. At times, the side effects associated with the cancer diagnosis are less severe side
effects than those associated with comorbid conditions and may lead to poor adherence

9

rates (Irwin & Johnson, 2015). One study found that in a sample of thirty patients, ten
patients had three or more comorbidities, while thirteen had one to two. The twenty three
patients all reported that oral treatment for their cancer greatly interfered with their ability
to manage their other conditions. This study also found that symptoms of chronic
conditions were often exacerbated by taking oral antineoplastic agents, leading to
decreased adherence (Given et al., 2015).
Nonadherence and Patients’ Belief in Efficacy and Psychological Barriers.
Belief in efficacy was a commonly reported factor among several studies that
found that if a patient did not feel that the oral chemotherapy was going to be effective,
they were not adherent to their therapy. Given et al. found this to be the most commonly
found factor affecting compliance, but also found that if patients had a strong belief in
efficacy, they may be overly adherent. Over-adherence includes when patients take more
than the prescribed dose or frequency of their medications, which places them at high risk
for adverse reactions, side effects, and death.
A prospective observational study conducted with 99 patients completing selfreported questionnaires related to adherence in Greece had similar findings and found
belief in efficacy to be a major barrier to adherence as well (Saratsiotou et al., 2010). The
purpose of the study was to study the patterns of treatment to oral chemotherapy. The
study included having participants completing anonymously a seven page questionnaire
which included demographic information, information regarding the type of disease they
had, treatment they were receiving, side effects they were experiencing, as well as issues
surrounding adherence.
While patients overall favored the ease of oral administration, 37.5% of
participants within the study felt oral may not be as effective compared to more
traditional routes (Saratsiotou et al., 2010). Sixty patients (61%) within the study reported
a belief that their treatment was going to be effective, eight felt that it would negatively
affect their disease (8%), and sixteen (16%) felt that it would merely stabilize their
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cancer. Nonadherence in those who did not believe that their treatment was going to be
effective was measured as high as 62.5% (n=5) as compared with those who did have a
belief in efficacy at 16.7% (n=10).
Characteristics related specifically to both the type of cancer as well as the stage
at which is it being treated can also weigh heavily on adherence with medication. In a
literature review with breast cancer patients (Moore, 2010), those who were
asymptomatic were less likely to be compliant as they perceived less benefit from
therapy. The purpose of the literature review was to assess the extent of nonadherence of
oral therapies in patients with breast cancer. Of note, this was a literature review and not
a systematic review, but looked at a total of 51 research articles spanning between 19932009. In her search, Moore also found that patients who were being treated at earlier
stages had higher levels of nonadherence as they did not feel as sick as those with later
stage diseases. Patients who were given treatment with the goal of prevention of either
recurrence or secondary disease also had lower rates. It is important to point out,
however, that a majority of studies reviewed were female patients on tamoxifen, which is
a hormone therapy and not classified as an oral chemotherapy. Belief in efficacy of
treatment often impacts survivorship, which is important to the longevity of patient’s life
expectancy and can greatly extend it.
Certain psychological issues may lead to adherence problems as well. For
instance, patients who are concerned about disease progression and death may be overly
adherent, taking more medication than was prescribed by their physician (Lester, 2012).
Over adherence is just as detrimental as under-adherence and high-risk patients with
known psychological issues should be assessed prior to initiation of oral therapy. Other
patients may be over stressed with the added responsibility of having to remember
additional information at a very stressful time in their lives. Patients can frequently
become so overwhelmed that they are incapable of retaining information such as dosing,
frequency, side effects, or when to take their medications (Lester).
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Nonadherence and Physical or Cognitive Impairment.
Advanced age plays a significant role in the ability to manage self-administration
of oral anti-neoplastic agents safely. Older patients may suffer from cognitive and
memory disorders which affect their ability to absorb information provided to them and
consequently to comply with prescribed treatment. Forgetting was cited in multiple
studies as a common cause for poor adherence.
One United Kingdom study of 43 patients with colon and breast cancer examined
this aspect of compliance using a self-reported survey (Bhattacharya, Easthall, Small,
Willoughby, &Waston, 2012). The purpose of this study was to assess factors that
impacts medicine taking habits of patients on the oral chemotherapeutic capecitabine.
Participants were recruited during an eight week period in 2009 by their healthcare
providers after being prescribed capecitabine for either breast or colon cancer.
Nonadherence was reported by 10 (23%) of the participants over the course of the study.
Forgetting a dose was the most frequently reported reason for nonadherence to
capecitabine. Participants reported that forgetting was deemed a more socially acceptable
form of nonadherence versus intentional behavioral patterns related to poor adherence.
Reported reasons included simply forgetting to pick up medication from the pharmacy,
forgetting education provided by healthcare providers on the medication in only verbal
form, as well as forgetting how and when to take medications (Bhattacharya et al.).
This older group of patients may also suffer from hearing and visual impairment
which can alter their ability to absorb education from healthcare workers and self-manage
at home (Moore, 2010). Visual impairment may cause the patient to inaccurately read
drug names, labels, doses, frequency, etc. and may cause medication errors (Bhattacharya
et al., 2012). One case study of a 60 year old patient with brain cancer who mistakenly
took in one dose the same amount of drug needed in three cycles of chemotherapy
spanning six weeks. This was due to the fact that her regimen was changed from one
drug, dosed in one capsule a day; to another medication that was taken as one capsule
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every three weeks. This patient unfortunately passed away from the error and her
misunderstanding of her new regimen (Spoelstra, 2015).
Nonadherence and Communication, Education, and Regimen Complexity.
Lack of patient education can also be found in the literature and is cited as a
common cause of unintentional nonadherence with patients. For patients being given
more traditional intravenous chemotherapy, nurses administering the medication are in an
excellent position to provide education. Both patients and caregivers are often present at
the clinic or infusion center for several hours, often over prolonged, periods of time
which provides healthcare providers ample opportunities to provide information. One
review of the literature by Hartigan (as cited in Hartigan, 2003) found that patient
education was considered most valuable at the beginning of treatment, prior to its
initiation. She further contended that one barrier to adherence is lack of verbal as well as
written instructions provided to patients and/or their caregivers. This information should
include; the name of the medication, dose and schedule, how it is to be taken, safety
concerns, side effects, and how to obtain symptom management.
The National Health Services in the United Kingdom conducted patient
satisfaction surveys which looked at various aspects of the patient experience while on
oral chemotherapy. While patients responded favorably to many questions, several had
poor responses in regard to aspects of patient education. For example, only 41% were
offered written information regarding their treatment, only 45% were educated as to
potential long term side effects, 65% reported having an opportunity to speak with a
healthcare provider in regards to practical concerns, and 44% reported having the
opportunity to speak with someone in regards to financial concerns (Quality Health,
2014).
Furthermore, the National Comprehensive Cancer Network in their Task Force
Report on Oral Chemotherapy found that patients are not always forthcoming or
complete in their communications with their healthcare providers. This can lead to issues
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when physicians and nurses need to be aware of current medications, diseases,
conditions, and lifestyle choices so they can be alerted to various contraindications to
certain treatments. This extends to healthcare providers’ ability to look for and monitor
side effects of oral chemotherapy in real time if patients do not report them. Delays in
doing so can result in delayed treatment and increased adverse effects to the patient. One
program that was assessed in the Task Force Report was the STAR program, where lung
and gynecologic cancer patients were encouraged to log consistently their side effect
either at each follow up or from home via an electronic database. In the study with 80
patients, 43 grade 3 to 4 toxicities were recorded and 7 warranted interventions (National
Comprehensive Cancer Network [NCCN], 2008). With increased and improved
communication with healthcare providers, several patients had better outcomes as a direct
result. It is evident from this data that not only is patient education a concern
internationally, but that more needs to be done to improve communication and education.
Chemotherapy regimens are complicated in the traditional inpatient or clinic
setting and self-administered oral medications are no different. Several studies have cited
this problem as a reason for decreased adherence among patients. Most regimens contain
at least two or possibly even more agents with multiple dosing. Additionally, cycling of
medications is common where patients have on and off days to keep track of. One study
found that approximately 67% of patients were being treated with complicated regimens.
This is a source of confusion for patients, especially when they are also on medications
for other conditions as previously discussed (Given et al., 2015). One example of a
complex regimen is seen with capecitabine which is commonly used to treat breast and
colorectal cancers. This drug is to be taken about 30 minutes prior to meals twice daily
and is a twenty eight day cycle where the patient will take medication for fourteen days
and then seven off, often concurrently with radiation. If regimens are too complicated for
patients to comprehend correctly, unintentional nonadherence may result.
Nonadherence in Hematology/Oncology Patients
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The number of patients being prescribed oral anti-neoplastic agents for the
treatment of cancer increases daily (National Comprehensive Cancer Network [NCCN],
2008). Adherence to these medications has been of concern to healthcare workers in the
past and continues to be a concern in the present. Unless the factors influencing
adherence are deciphered, nonadherence will continue to plague future patients as well. It
is estimated that 125,000 deaths per year can be attributed to non-adherence and is
accountable for 10-23% of both hospital and skilled nursing home admissions (Moore,
2010). The World Health Organization estimates that patients on average are only 50%
adherent with oral medications (World Health Organization, 2003). Nonadherence with
oral medications is not specific to hematology-oncology patients, but this population
poses very specific barriers as evidenced by the following literature.
Nonadherence with Oral Chemotherapies.
The oral medications used to treat cancers of all types are often thought by many
patients to be less potent than their counter parts by other routes. However, their side
effect profiles are often comparable, while some may have even more adverse effects.
Side effects are generally similar to other chemotherapies and can include mucositis,
diarrhea, nausea, vomiting, rash, fatigue, and more depending on the specific medication.
A study conducted in Australia found that only 20% of the 15 participants in a nurse-led
clinic knew the main side effects associated with their medication(s). It also found that
only 53.3% of patients knew to report poorly controlled symptoms to their nurse or
physician, only 40% knew how to correctly use their antiemetic medication, and only
13.3% how to use their antidiarrheal medications (Griffiths & Pascoe, 2014).
As noted in Spoelstra et al. (2013), many patients also have comorbidities and the
treatment for those conditions can lead to increased side effects and toxicities when
combined with oral anti-neoplastics. Patients may also experience anticipatory side
effects such as nausea and vomiting which will greatly affect their adherence if not
properly managed. This information as further supported in a literature review looking at

15

tools to increase adherence within the hematology/oncology population
(Burhenn&Smudde, 2015). Side effects may also decrease absorption and metabolism of
drug due to nausea, vomiting, and diarrhea. One study of capecitabine, previously
described, found that patients even reported non-adherence related to neuropathy caused
by the medication that prohibited them from getting the medications out of the blister
packing (Bhattacharya, Easthall, Small, Willoughby, &Waston, 2012).
Although some anti-cancer drugs have been around for quite some time, emerging
therapies often remain exorbitant. This can affect a patient’s compliance if they are not
able to afford the medication as prescribed. Furthermore, even though more
chemotherapeutic drugs are being covered by insurance benefit plans, due to the
relatively new nature and costs of several drugs, many patients are restricted to older
treatments that are covered by their insurance. One study discovered that 25% of 10,508
patients analyzed from a pharmacy database were paying on average $500 per month in
co-pays for oral chemotherapies. It also found that up to 50% of this group of patients did
not return to the physician or for follow up to obtain a different medication within 90
days. The same study looked at the price per month for different oral chemotherapies and
revealed that patients with medullary thyroid cancer prescribed either cabozantinib or
vandetanib costs anywhere from $12,644.28 - $30,690.31 monthly (Bwayo-Weaver,
Moore, Shah, & Serlemitos-Day, 2013). Another research study found that oral antineoplastics can cost anywhere from $10,000 to $100,000 annually per course of treatment
for one patient (Rittenberg & Spoelstra, 2015)
This has lead patients to ration medications or not have prescriptions filled at all
due to costs. This is seen often in individuals with high deductibles or with incomplete
coverage and can lead to failure of treatment. Applications for financial assistance are
commonly long and complicated for most patients who tend to give up and not complete
them. Issues with prior authorization requirements by insurance companies can also be
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time-consuming and complicated for healthcare providers and can take several days for
approval which can lead to a delay in treatment (McMahon &Rudnitzki, 2015).
It is clear from the above findings within the literature that nonadherence is a
multi-factorial issue. Problems range from surrounding the healthcare system, to the
nurse or healthcare provider, to the patient and their caregivers themselves. Given this
fact, the answer to this concern should also be multi-factorial as well and providers
should aim to learn from the reasons for nonadherence and apply that knowledge to
circumventing it whenever possible.
In the next section, the critical appraisal framework used to guide this systematic
review will be presented.

Critical Appraisal Framework
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses, or
PRISMA, was designed to increase the quality of reporting for both systematic reviews as
well as meta-analyses. It consists of a 27 item checklist that dictates the minimum
requirements for evidence- based studies and is utilized as a critical appraisal tool
(PRISMA, 2009). Items on the checklist include seven major headings: title; abstract;
introduction; methods; results; discussion; and funding. Within each heading are
subheadings as well as descriptions defining the expectations for each of the sections. In
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addition to the checklist, PRISMA also contains a flowchart, which guides researchers in
the literature search process. The flowchart dictates how to screen and evaluate for
eligibility within the research based on the study purpose and question.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses began
originally as the Quality of Reporting of Meta-Analysis (QUOROM) statement in 1999
as there was a call for a standardization and improvement upon the quality of systematic
reviews as well as meta-analyses (Atlman et al., 2009). It was found that information
being reported within these studies was of poor quality, poorly presented, and therefore
of little assistance in establishing quality standards of care for patients. In 2009, the
statement underwent an overhaul and was recreated as PRISMA. This change was
prompted as systematic reviews had increased in numbers in this time frame, as
evidenced by the increase of submissions in the Cochranes Library’s Methodology
Register (Atlman et al.).
Additionally, the potential risk for bias within a systematic review or metaanalysis was becoming widely recognized, requiring additional guidelines to be put in
place. The changes that were developed were in response to a remaining consistent level
of poor quality systematic reviews being produced. Additions in the form of the flowchart
and checklist were made in an effort to increase transparency of reporting even further.
The flowchart was altered to included the number of articles identified, those included, as
well as those excluded. The 27 item checklist was created with items deemed necessary
for transparency of data.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
statement itself was developed by 29 consumers, clinicians, review authors,
methodologists, and medical editors. Items that all members deemed necessary for
transparent research were all included in the checklist of 27 items. The items on the
checklist include, but are not limited to the title, objectives (research questions), search
strategy, study selection, data collection process, summary of evidence, and conclusion.
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This gives researchers a step by step guide while allowing them to present their research
in a conclusive and succinct manner (Appendix A).
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses not
only provides a checklist, but contains a flowchart which assists in obtaining the
appropriate research. This flowchart also provides a step-by-step set of instructions which
dictates which articles are retained for the final paper. It also reminds the researcher to
include an explanation for the exclusion of articles which further increases the
transparency of the study. It begins with the identification of articles, the screening of
those articles for appropriateness and eligibility, and ends with the articles to be included
within the research (PRISMA, 2009)- (Appendix B).
The world of systematic reviews and meta-analyses continues to evolve and grow
and so has the format used to evaluate them. At the beginning of 2015, an additional
group of experts in research assembled to extend the PRISMA statement to look at a
newer subset of a meta-analysis with greater than two interventions, which is called a
network meta-analysis (Hutton et al., 2015). This change led to the addition of five more
items to the checklist for a total of 32 items. All additional 2015 changes can be found
within the methodology section of the checklist and reflect the goal of decreasing biases
in reporting.
For the purpose of this systematic review, the researcher utilized the original
format of the checklist created in 2009. This was due to the fact that only two variables
were examined, oral anti-neoplastic agents and barriers to adherence. Both the checklist
as well as the flowchart were utilized to obtain, evaluate, and report findings in order to
maintain the completeness and transparency of the research performed. This framework
was chosen in order to decrease the bias of reporting in the course of this study.
The methods utilized in this systematic review will be presented next.
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Method
Purpose of Study
The purpose of this systematic review was to identify causes of nonadherence to
oral chemotherapy on the part of the patient and their caregivers. The question posed
was: What are the barriers to adherence with oral chemotherapy among the adult
hematology-oncology patient population identified in recent literature? The outcome
assessed was the most prevalent barriers to adherence.
Inclusion and exclusion criteria
The inclusion criteria included: studies pertaining to subjects 18 years or older,
studies using only medications classified as oral anti-neoplastics, only those studies
which are either qualitative or quantitative; and those studies that examined barriers to
adherence to oral chemotherapy. The exclusion criteria included: non-English articles;
non-nursing research; hormone therapies; adherence studies that are not related
specifically to oral anti-neoplastics; chemotherapy administered other than via the oral
route; and research before 2010.
Search Strategy
Utilizing both the PRISMA flowchart (Appendix C) as well as the PRISMA
checklist (Appendix A), this investigator collected data from Nursing Reference Center
powered by EBSCO and OVID. The search was conducted using the terms adherence,
oral anti-neoplatic agents, oral chemotherapy, barriers to adherence, patient compliance,
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and patient non-compliance with oral chemotherapy. The results yielded in this search
were applied to the PRISMA flow diagram to assist with article selection. The process
began with tabulating the number of articles found through the database search as well as
others located through different sources. After removing any duplicates located, the
investigator assessed the remainder as well as those excluded in this process. Initial
research involved reviewing both title and abstract for eligibility and articles were be
omitted if criteria were not met. The remaining were then further screened for eligibility
and the reasons for exclusion of those that did not qualify were noted. At this point, the
number of articles being utilized for data synthesis were identified (PRISMA, 2009).
Data Collection and Synthesis
Following the collection of articles, each one was meticulously reviewed and data
were extrapolated. Data collected included types of non-adherence frequently seen in the
research of patients prescribed oral chemotherapy and relevant statistics related to this
information. Data was also collected on the various types of studies that were conducted
in the research of each article. A chart was constructed and utilized to organize
information extrapolated from articles which was adapted from an article by FineoutOverholt et al. (2010)- (Appendix B) . The data collection tool included title, year
published, author(s), design method, sample, setting, major variables within a study,
limitations, and findings related to barriers to adherence. Consistency in key terms was
applied in order to accurately and succinctly represent the data.
The PRISMA checklist (Appendix A) was utilized throughout to ensure
completeness of findings and data summaries. The results section includes the
characteristics of a given study, any potential bias noted, results of individual studies,
how results were obtained, and any additional data collected. It was further used to
discuss the summary of the evidence obtained, potential limitations, and conclusions
(PRISMA, 2009).
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In addition, charts were constructed to include the information from the PRISMA
flowchart including- the number of articles, those obtained initially, those omitted, and
the final number. This flowchart is a direct outline based on the PRISMA flowchart itself
(Appendix C). Another was constructed to look at the main barriers types seen and will
include common subsets within these headings.
Critical Appraisal Tools:
The critical appraisal of the data was made via the Critical Appraisal for
Summaries Evidence, or CASE, worksheet (Appendix D).The authors (Foster & Shurtz,
2013) aimed to develop a reliable tool to critically analyze evidence based point of care
information? The authors identified five systematic reviews and greater than 100 primary
articles following a literature review in CINHAL, EMBASE, MEDLINE, PsychINFO,
and ERIC. Based in the information obtained from this search, the authors became aware
of the importance of including in their worksheet information about of how evidence was
both obtained and evaluated. It also had a moderate level of reliability among the rating
of 384 summaries and was used to assess overall quality of evidence based practice. The
CASE was developed using 10 questions that could be answered with either yes, no, or
not completely (which applies to studies which possess incomplete data). Following each
question, there are additional probing questions to assist researchers in answering the ten
questions accurately. The questions within the worksheet include those pertaining to;
topic, methods, content, and possible application to practice (Foster &Shurtz, 2013).
The CASE worksheet was used to systematically assess the quality of research
yielded from the final number of articles selected for the purpose of this study. It
reviewed the “specificity, authorship, reviewers, methods, grading, clarity, citations,
currency, bias, and relevancy” (Foster &Shurtz, 2013, p. 192) of the articles on an
individual basis. The chart was also used to calculate the percentages of different barriers
seen within the articles in order to identify those seen more frequently and their
associated causes. Additionally, data was analyzed from the chart to examine the various
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types of studies to increase the level of transparency and quality of research examined.
Discrepancies found when comparing research studies was addressed in the synthesis of
data as well (Appendix D).
This study was performed without funding by a party that may increase bias of
reporting on the part of the investigator. No conflicts of interest are included in the
development of this project as well.

Results
The original search terms yielded 2046 studies, 1146 remained after removal of
duplicates, and 1094 were eliminated following review of both title and abstract. Fiftytwo articles were retrieved in full text and reviewed by the author; another 35 were
excluded as they did not fit inclusion and exclusion criteria. During data extraction two
additional articles were excluded upon further review as they in fact did not meet criteria,
yielding an N of 15 full text articles. The reasons for exclusion of the majority of articles
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included: did not pertain to oral chemotherapy; non-nursing research; and examined
nonadherence in regards to other conditions such as HIV/AIDS, diabetes, and posttransplant patients. A flowchart illustrating selection of studies is depicted in Figure 1 on
the next page.
All studies were summarized in a data extrapolation chart (Appendix E). The
findings were broken up into three main categories: patient related; system related; and
nurse/provider related. Findings related to barriers to adherence from the articles were
then placed in appropriate categories as illustrated in Table 1.
Table 1.- Reasons for Patient Nonadherence to Oral Chemotherapy
Reasons for Patient Nonadherence to Oral Chemotherapy
Patient-Related

System-Related

Nurse/ProviderRelated

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Adverse effects and toxicities (n= 9)
Forgetfulness (n=4)
Belief in efficacy (n= 2)
Depression (n=2)
Cancer type (n= 2)
Comorbidities (n= 1)
Regimen complexity (n= 6)
Financial (n= 4)
Pharmacy availability/locating specialty pharmacies (n= 3)
Time constraints of staff and poor staffing (n= 3)
Length of treatment (n= 1)
Patient education (n= 8)
Frequency and length of follow up visits (n= 5)
Nurses level of education/experience (n=2)
Physician experience (n=1)
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Figure 1. Process for study collection utilizing the PRISMA Flowchart (N= 15)
Patient-Related Factors
Within the heading of patient related, the most commonly cited barrier was
adverse effects and toxicities as a result of oral chemotherapy were found in nine studies
(Appendix F- # 1, 2, 3, 5, 6, 9, 13, 14, 15). Roop (2014; Appendix F #1) found that
adverse effects were the second most prevalent cause of nonadherence (72%) in a
descriptive study of 577 oncology nurses. Nurses within the study also reported that
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patients frequently did not call with adverse effects as they felt they were bothering
providers; others opted to “tough it out” or were more afraid of their cancers than they
were of the side effects. Effects may increase to the point where patients decide to stop
their oral chemotherapy medications altogether, but may not notify their physician
(2014).
A qualitative meta-analysis with quantitative synthesis (Irwin & Johnson, 2015;
Appendix F #2 ) found that as many as 69.8% of patients reported adverse effects as their
cause for autonomously ceasing their treatment. The study of 159 full text articles also
found that some patients will intentionally alter their dose or frequency in an attempt to
combat those adverse effects. Adverse effects were shown to have a 40% frequency
effect size from qualitative studies examined. Several studies within the meta-analysis
found that improved management of symptoms increased rates of adherence (2015).
The three group pilot study of 119 patients conducted to assess the utilization of
different interventions to increase adherence revealed that 80% (n= 95) of patients had
the presence of at least one or more symptoms (Spoelstra et al., 2013; Appendix F #3).
The patients were assessed by a registered nurse (RN) seven days following initiation of
their oral chemotherapeutic agents and rated symptoms on average a four or more on a
scale of 0-10. These patients were assigned to group two and were provided an RN to
continue to follow up and assist with the management of their symptoms. Group one
subjects were referred to materials to assist with self-management of symptoms and
group three were called by an RN to assess adherence. Group two was found to have the
most significant decrease in symptom severity, down 6.76 as compared with group 1
(4.74) and group 3 (2.16). The study also found that within group 2, although originally
with the highest rate of nonadherence, rates decreased with each week of the study,
suggesting that improved symptoms increased rates of adherence. This finding is
consistent with a study conducted via a focus group of patients either past or present on
oral chemotherapy (Simchowitz et al., 2010; Appendix F #5). Patients expressed that they
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did not feel comfortable managing their adverse effects and they often affected adherence
rates.
In a descriptive feasibility pilot study (Sommers et al., 2012; Appendix F #6) of
30 patients with gastrointestinal cancer at an outpatient oncology center, it was
discovered that 17 (57%) patients reported adverse effects within 72 hours of initiating
oral chemotherapy. Eight out of the 17 (57%) patients required further assistance
managing their effects while on oral chemotherapy. Seven patients had therapy stopped
due to toxicities from their treatment and it was found that most patients could not
articulate drug specific side effects to report to their providers. The importance of
managing adverse effects of oral chemotherapy can be easily demonstrated as was seen in
one systematic review of 131 articles (Sansoucie and Spoelstra, 2015; Appendix F #9).
This review found that most interventions to increase adherence were targeted to
managing symptoms. Interventions geared towards the management of adverse effects
were listed as recommended for practice to increase adherence.
Another systematic review found that the most common treatment-related reason
for nonadherence to oral chemotherapeutic agents included adverse effects to treatment
of various cancers (n=5) (Verbrugghe et al., 2013; Appendix F #14). The studies
analyzed focused on breast, chronic myeloid leukemia (CML), and colon cancer; the
most common being breast. One study found that as many as 70% of patients within that
study reported nonadherence related to symptom severity. The authors recommended
early intervention and education about side effects to patients on oral agents (2013). This
is consistent with another study qualitative study where of the 10 patients who were
intentionally nonadherence, the most common reason noted was due to adverse effects or
in an attempt to minimize side effects experienced by the patient (Eliasson et al., 2011;
Appendix F #15). This study was conducted on patients taking imatinib for the treatment
of CML.
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One descriptive exploratory study of 30 oncology patients with comorbidities
found that patients averaged 5.1-5.6 on a symptom severity scale of 1-10 (Given et al.;
2015; Appendix F #13). Those patients with the higher number of comorbid conditions
reported higher levels of adverse effects and often felt that the management of their
cancer and side effects interfered with the management of their other conditions which
led to decreased adherence rates at times. There was also a relationship found between
younger age and increased symptoms severity which may be attributed to more
aggressive treatment in younger populations leading to potentially decreased adherence
rates (2015).
The second most common patient-related factor noted in the research pertained to
patient forgetfulness when taking their prescribed oral chemotherapeutic agent (Appendix
F- # 2, 10, 14, 14). Irwin and Johnson found that forgetfulness was the most commonly
reported reason for unintentional nonadherence in patients (2015: Appendix F #2). Their
meta-analysis found a 38% frequency effect size from qualitative studies and 27 articles
listed forgetfulness as a common cause of nonadherence out of the 159 within the study.
Mathes et al. (2014; Appendix F #10) found in their systematic review that
forgetfulness was cited by numerous authors and their studies were directed at
interventions to address this aspect of nonadherence. Of the six studies included in the
review, one showed the intervention to have statistical relevance in increasing adherence,
three studies were in favor of interventions, and two had mixed results. The interventions
utilized and studied were primarily medication reminders for patients or Medication
Event Reporting Systems which records when a patient opens their medication bottle to
assess for missed doses as well as patient education. Another systematic review by
Verbrugghe et al., (2013; Appendix F #14) found that forgetting was the most common
cause of unintentional nonadherence (n=2).
System-Related Factors
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Within the heading of system related factors, one of the most commonly seen
factors was regimen complexity (Appendix F- # 1, 2, 3, 4, 7). Roop and Wu (2014;
Appendix F #1) found in their national online survey that the largest perceived barrier
from nurses to patient adherence was in relation to complex regimens (n= 237: 41%).
These nurses felt that complicated directions for medication administration was the
number one reason for nonadherence among their patients. Several reported that they
have had some success with the implementation of follow up phone calls as well as
medication calendars.
Complexity of a patients’ oral chemotherapy regimen was also cited by Irwin and
Johnson (2015; Appendix F #2) as a cause of nonadherence in their meta-summary
analysis. Although the evidence was not as strong as was seen with some other factors
analyzed, there was a 22% (n=14) frequency effect size from the qualitative studies
examined. The authors suggested, however, that lack of research pertaining to this topic
was in part why there was not more evidence to support it as a more significant cause of
nonadherence. This is supported by a pilot study (Spoelstra et al., 2013; Appendix F #3)
which found that with increased complexity, there was also an increased in missed doses
of medication. Patients within the study who were on continuous regimens had an
adherence rate of 88% versus those on a 14 days on and seven days off regimen which
had only a 35% adherence rate. Additionally, for those on a seven days on and seven days
off regimens, only 33% were adherent and all other types of complex regimens were
found to have on average only a 50% adherence rate.
The secondary analysis of the previous study mentioned looked at the effect of
regimen complexity on over-adherence (Spoelstra et al., 2013; Appendix F #4). Overadherence is defined by WHO as occurring when a patient takes greater than the
prescribed amount of medication, either in dose or frequency (2003). The research found
that of the patients with a simple continuous regimen, only one was overly adherent as
compared with those patients on regimens with 14 days on and seven days off which had
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12 patients who reported over-adherence. Patients with regimens with seven days on and
seven days off had six report over-adherence during their cycle. Over-adherence also
places the patient at risk for adverse effects and toxicities which can also affect adherence
rates as previously described.
In addition to regimen complexity, financial barriers were common reasons for
nonadherence (Appendix F- # 1, 2, 5, 14). One study surveying oncology nurses found
that 81% (n=467) felt that cost of oral chemotherapy was the largest cause of
nonadherence (Roop & Wu, 2014; Appendix F #1). Many felt that high cost of drugs also
made it more difficult to obtain authorization through insurance companies causing
delays in administration. Additionally, when there were high out-of-pocket costs for
patients and financial assistance was required, applications were long and tedious which
further delayed treatment. Nurses expressed concerns that at times chemotherapy
teaching occurred long before patients were able to physically obtain the medication due
to cost which may have affected information retained by patients provided in the teaching
sessions (2014).
Irwin & Johnson (2015; Appendix F #2) in their meta-analysis found that cost of
medication was a common cause of unintentional nonadherence for patients. The study
found that there was a 26% size effect with cost of oral chemotherapy affecting
adherence and was supported by 19 studies out of the 159 analyzed. Simchowitz et al.
(2010; Appendix F #5) also found that cost and insurance were frequently a common
reason for a patient’s inability to take medication as prescribed. Patients within the focus
group articulated that there were frequent issues negotiating costs with insurance
companies in order to be able to afford their medication. Others reported that they often
required assistance from the pharmacist, nurse navigator, family, and even a United
States Senator for assistance in obtaining coverage for their oral chemotherapy (2010).
Financial hardships for patients in relation to out-of-pockets costs for medication is
further supported by Verbrugghe et al. (2013; Appendix F #14,). The authors found that
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even a copay as low as $30 may prohibit many patients from being able to afford their
medication. Higher out of pocket costs were associated with poor adherence in patients
being prescribed oral chemotherapy in the study.
Nurse/Provider-Related Factors
There are also several nurse and provider related factors that have the potential to
affect patient adherence on oral chemotherapy. The most commonly seen within was in
relation to patient education (Appendix F- # 5, 6, 7, 8, 9, 10, 11, 14). One study which
performed a focus group with both current and former patients prescribed oral
chemotherapy expressed a desire for increased education related to their medication
(Simchowitz et al., 2010; Appendix F #5). Many patients within the study felt they were
ill-prepared to be aware of side effects to expect, how to manage them, and when to
report side effects to their providers. They also expressed a desire to have been informed
more thoroughly what symptoms were considered normal based on their particular
medication versus what was a “red flag” to be reported immediately to providers. Many
also felt that they retained very little from their original education session and felt that it
would be beneficial to have frequent reinforcement and additional information provided
to them (2010).
Sommers et al. (2012; Appendix F #6) found in their study of 30 patients that 21
(70%) could not identify the most common adverse effect related to their medication.
None of the patients in the study on temozolomide (n=5) could verbalize understanding
or identify that hematologic toxicities were associated with the medication. Another 50%
of patients within the study (n=3) on sorafenib were unable to identify hypertension as an
adverse effect associated with their medication or to monitor their blood pressure. The
investigators found that follow-up phone calls from the nurse to reinforce information
discussed at teaching visits was helpful in minimizing non-adherence related to
knowledge deficits (2012).
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The authors of an Australian study who conducted an education program for
patients on oral chemotherapy found some staggering results in relation to patient
education (Griffiths & Pascoe, 2014; Appendix F #7). Prior to patient education being
provided, only 46.7% (n= 7) of the 15 patients in the study could correctly identify the
name of their medication as compared to 100% following education. Only 66.7% (n=10)
knew when to take their medication and only 60% (n=9) knew how many tablets to take
at a time versus following education where rates increased to 100% for both questions.
Investigators in the study also found that only a mere 20% (n=3) knew the main adverse
effects associated with their specific oral chemotherapy medication, this rate also
increased to 100% following the education program. In relation to medication safety,
none of the patients within the study could accurately articulate to researchers where a
safe place would be for them to store their medications (2014).
Another study conducted in Japan surveyed nurses on their perceptions of their
practice related to patients on oral chemotherapy (Komatsu et al., 2014; Appendix F #8).
Nurses reported that only 58.1% (n= 36) assessed their patients understanding of their
medication as well as 75.8% (n= 47) provide education to their patients on how to
manage their adverse effects. Of the nurses who participated in the survey 64.5% (n= 40)
responded that they confirmed patient understanding of their medication regimen,
however 93.5% (n= 58) stated that if their patients articulated that they did not
understand they provided them with additional information.
Patient education as the sole intervention on adherence was found to have little
evidence to support use, but was found to be recommended for practice when combined
with other modalities such as reminders and close follow up (Sansoucie & Spoelstra,
2015; Appendix F #9). Some studies analyzed in the systematic review did show a
positive effect on patient adherence while others were inconclusive or with mixed results.
Researchers found, however, that when used in conjunction with other techniques,
education was very effective in assisting patients. Ten random control trials (RCTs)
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found that when used in combination with other interventions, there was a significant
increase in adherence rates. Research conducted on education as a sole intervention was
found to have mixed results with five studies showing a positive effect on adherence
while another four found no effect. Another systematic review conducted in Germany
found that of the six articles in their study, two utilized patient education as part of their
interventions to increase adherence and found positive results (Mathes et al., 2014;
Appendix F #10). Of note in this study, data was not reported on statistical results of
adherence and no control group was utilized in either study.
One study utilizing in-service programs, which were conducted in various
healthcare settings across the northeastern United States, found that nurses often did the
not have the tools or knowledge to provide personalized education to patients to increase
adherence (Matthews & Holland Caprera, 2014; Appendix F #11). Based on the survey
of nurses present at the in-services, the researchers articulated the need for increased
education for patients and caregivers regarding their oral chemotherapy in order to
prevent nonadherence as well as to prevent adverse effects which also may lead to
nonadherence. They further stated the need for follow up after initiation of therapy to
provide reinforcement of education and possible interventions as needed. No specific data
regarding the survey administered to nurses was provided nor was understanding of
providers knowledge of the oral chemotherapies (2014).
The systematic review conducted by Verbrugghe et al. (2013; Appendix F #14)
found that of the 25 studies included, several (n= 4) found that lack of or poor patient
education contributed to lack of consistent patient adherence with oral chemotherapy,
while an others (n=3) found a positive effect on adherence with increased knowledge and
education prior to initiation of treatment. One study found a lack of education regarding
the consequences of nonadherence, another found similar results in regards to poor
patient education on potential adverse effects and what to report. One study found a lack
of education to patients prior to initiation of chemotherapy during the review of treatment
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options available and stated that more information would have assisted patients with
making different choices regarding their chemotherapy. Another study found a general
lack of knowledge and education from providers in regards to their disease, prognosis,
and treatment options. Findings an overall need for increased patient education in all
areas of care along the continuum (2013).
The second most commonly seen theme within the nurse and provider-related
heading was related to follow-up with patients on oral chemotherapy affecting adherence
rates (Appendix F- # 3, 5, 6, 11, 14). Spoelstra et al. (2013; Appendix F #3) found that
within their three control groups, the one that provided patients with the Automated
Voice Recording (AVR), nurse follow up calls, and interventions as needed for
symptoms had the lowest rates of nonadherence (33%). This compares with the first
group which only received the AVR (40%), and the third group which received the AVR
as well as the nurse follow-up calls, but without interventions (53%). All Results from all
groups supported that with increased number of contacts with the patients, the rates of
adherence increased over time (2013).
Another study conducted via a patient and caregiver focus group found that
although all patients within the group reported follow-up with their providers, there was a
wide variety between what type of follow-up and how often (Simchowitz et al., 2010;
Appendix F #5). Many patients within the study expressed a need for follow-up with
providers in-between appointments, specifically in regard to the management of their
symptoms. They felt that all of the responsibility fell upon them as the patient to call and
report symptoms. Several patients also felt that they were often unsure what to report and
what symptoms were considered expected and did not always feel comfortable calling
their providers. Some patients who had previously been part of a clinical trial felt that
they were left on their own and were upset by lack of follow-up as compared with being
part of a clinical trial where follow up was performed frequently and symptoms were
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monitored closely. There was an overall agreement that follow-up of those on oral
chemotherapy should reflect that of patients on clinical trials (2010).
Sommers et al. (2012; Appendix F #6) performed a study that included a followup call to patients from an RN 72 hours after initiation of oral chemotherapy treatment.
They found that at that time, most patients had begun to experience side effects from their
medications and reported increased satisfaction with the increased follow-up. Nurses
were able to assess side effects, answer questions, assess needs of the patient and their
caregivers, and refer to a provider as needed. They also found that patients were not able
to articulate to nurses what side effects to reports, what were specific to their particular
medication, or how to manage their side effects. The call from the RN allowed for
interventions as needed, increased education, and triggered follow up with providers if
needed as well (2012).
Many nurses and physicians reported frustration in regard to time constraints
prohibiting or limiting their ability to provide increased follow up with patients on oral
chemotherapy (Matthews & Holland Caprera, 2014; Appendix F #11). Providers included
in the survey communicated that they often spent large amounts of time obtaining
authorization for medications, finding pharmacies that carry the medication, and
obtaining financial assistance as needed, which decreased time spent with patients and
with appropriate follow up. Several nurses in the study felt that decreased time spent
talking with patients had the ability to decrease adherence for several reasons including
knowledge deficits and adverse effects. They also articulated a lack of individualized
follow up plans for each patient based on their specific needs such as in regards to
transportation or work schedules which may require a follow up telephone call versus
being seen in person.
One systematic review also found a correlation between follow-up and effect on
adherence with patients being prescribed oral chemotherapy (Verbrugghe et al., 2013;
Appendix F #14,). One study reported that short duration of follow-up appointments had
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a negative effect on adherence. This negative effect was also seen with three other
studies, which found that follow up with providers other than their attending oncologist
had the potential to decrease patient adherence rates. Conversely, longer duration of
follow in addition to an increase in the number of follow up appointments with providers
were seen in two studies as having the ability to increase patient adherence in CML
patients.
Other data extrapolated was presented in further details in appendix F.
Next, summary and conclusions will be presented.
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Summary and Conclusions
Currently 25% of new cancer drugs in development are via the oral route and this is
expected to continue to grow (Verbrugghe et al., 2013). Research collected in this
systematic review showed that healthcare providers are struggling with chemotherapy
administered orally due to its’ relative newness. Currently few institutions have adequate
policies and procedures in place to monitor patients on these medications (Roop & Wu,
2014). Patients have reported a lack of follow-up, verbal and written education,
information regarding adverse effects and availability of providers to answer questions
regarding their oral chemotherapy treatment (Quality Health, 2014).
With an estimated death rate of 125,000 patients annually due to nonadherence to
oral chemotherapy as well as a 10-23% increase in skilled nursing facilities and hospital
admissions, there is clearly a need for increased focus on this issue (Moore, 2010). With
reports that as high as 40% of patients are lacking knowledge related to how to correctly
self-administer their oral chemotherapy medications (Griffiths & Pascoe, 2014), it is
obvious that additional emphasis, resources and education are needed. This is further
supported by documented lack of financial resources for many individuals given that
costs of oral chemotherapy medications can range from $12,644.28-$30,690.31 monthly
(Bwayo-Weaver et al., 2013).
There is a steep learning curve for healthcare providers who provide care for
patients on oral chemotherapy. There are also crucial differences in the care provided as
compared to those who receive intravenous chemotherapy. Patients on intravenous agents
often experience more frequent assessments and interventions since the medication is
administered in a clinic or infusion center by nurses who assess them. Additionally, many
intravenous regimens necessitate that patients be seen for infusions as often as daily, for
several consecutive days, which facilitates close assessment.
The purpose of this systematic review was to identify causes of nonadherence to
oral chemotherapy on the part of the patient and their caregivers. Studies were selected
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through a comprehensive literature review using selected key terms. The initial search
yielded 2046 studies; next duplicates were removed and inclusion and exclusion criteria
were applied. A final total of 15 studies met all of the pre-set criteria. The most prevalent
barriers to adherence that were identified were categorized into three common themes:
patient-related factors; system-related factors; and nurse and provider-related factors
which were then broken down further, with findings appropriate to the respective themes
identified. Certain themes were seen with increased frequency in the, including adverse
effects, patient forgetfulness, regimen complexity, financial barriers, patient education,
and necessary follow up. This suggests that these factors should be carefully assessed by
providers caring for these patients.
There were certain limitations that existed in conducting this systematic review.
During data collection and initial analysis of the available research, it was evident that
there were only a small number of studies pertaining to patients taking oral chemotherapy
specifically: this affected sample size which was relatively small. Several studies relied
heavily on patient self-report which is subject to the Hawthorne effect and may be
inaccurate. Two systematic reviews (Irwin & Johnson, 2015; Mathes et al., 2014)
included studies of poor methodological quality which may have affected the results
conveyed. Also, adherence rates were difficult to assess and compare given the fact that
criteria for adherence varied greatly from one study to the next and without a consistent
definition. For instance Verbrugghe et. al (2013) found that researchers considered a
patient non-adherent if they took their medication anywhere from <80% to <100% of the
time and were over-adherent if they took >110% of their prescribed medication . Another
study defined a patient as under-adherent if they missed greater than 20% of their
medication within a seven day period (Spoelstra et al., 2013). Yet another study defined
optimal adherence as occurring when a patient takes all doses of a medication, every day
at the right time, without missed or extra doses (Komatsu et al., 2014).
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In conclusion, nonadherence in patients who are prescribed oral chemotherapy
will continue to be a problem as the number of oral oncolytics continues to increase. The
researcher was able to shed light upon the fact that nonadherence is related to multiple
and diverse factors and thus one intervention alone will not be successful in
circumvention. Care of patients taking oral chemotherapy needs to be highly
individualized and the nurse has an important role in the monitoring of this vulnerable
population. Nonadherence is multi-factorial with many variables for healthcare
professionals to consider. Numerous opportunities exist to improve care of people
prescribed oral chemotherapeutic agents and these will be discussed in the next section.

Recommendations and Implications for Advanced Nursing Practice
The information collected and analyzed in this study has provided evidence for
recommendations for practice changes among advanced practice nurses (APNs). There
was a lack of nursing education and knowledge pertaining to the issues surrounding
potential barriers to adherence among new and existing nurses in the research. With the
large increase of the number of available oral therapies available and being ordered for
patients, nurses need to be abreast of the adverse effects and implications for both the
patients and their caregivers to help them circumvent potential issues. This also extends
to novice nurses coming into the field as well.
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Schools of nursing need to provide education to both undergraduate and graduate
students in regard to adherence of patients on oral medications so that they are aware of
this challenge in their practice. Likewise, the potential causes of nonadherence, the risks
associated with nonadherence, and strategies to assist with decreasing its’ incidence need
to be addressed. Future APNs should understand that they will need to provide education
within their respective roles to both patient and healthcare staff alike on the topic.
Hospitals and other healthcare institutions can include the topic within their new staff
orientation and maintain the knowledge through annual competencies. As rates of
readmission increase, which costs institutions as well as providers reimbursement, it
certainly behooves them to maintain a focus on this issue at consistent intervals. The
APN has a vital role in also discussing these issues of noncompliance with other team
members and physician colleagues.
Increased communication among all healthcare providers caring for patients
taking oral chemotherapeutic agents is key to improving outcomes. Studies identified that
patients want increased information as well as options in their care including adverse
effects to expect and report. Increased follow up with consistent providers increased
patient adherence to their regimens which is an important factor as well. Attempts to
maintain and increase consistency of providers represents an important leadership role of
the APN. Nurses articulated in several studies the need for increased communication
between interdisciplinary providers of patients on oral chemotherapy to increase their
assessment of the patients. As with all aspects of nursing and in healthcare in general,
communication from provider to provider in addition to from provider to patient is highly
crucial to provide the best possible care to patients.
Several studies which collected data from nurses also found a deficit in the
availability or accessibility of policies to guide nursing practice related to patients on oral
chemotherapy regimens. It is recommended that all patient care areas which administer
these potent medications have policies and procedures in place and accessible to all staff
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to refer to in order to increase patient safety. These policies should include, but not
necessarily be limited to, how to manage patients, follow up needed and how often, how
to track patients on these medications in the medical records, as well as how nurses
should be notified that a patient is being placed on the medication by the providers.
Policy development most certainly falls under the umbrella of roles for the APN as it
pertains to increasing patient outcomes and overlaps with evidence based practice (EBP).
The APN is in a position to provide expertise in the development of policies and
protocols given their education and knowledge of EBP which is a necessity in their
development. All policies and protocols created need to be backed by evidence to support
their statements and positions. Additionally, the APN is important for the implementation
and education of staff about their existence, as well as how to use them and when.
Nursing leadership also plays an important role in bettering the outcomes of this
patient population as well. There are often difficulties obtaining insurance coverage or
affordable co-pays for patient’s on these medications. Many insurance companies do not
cover oral chemotherapies, require prior authorizations, additional research to be
submitted to prove potential efficacy, or have incredibly high out of pocket costs. The
APN is in prime position to act on legislation to ensure coverage for these life saving
medications for all patients who should not have to choose between a less effective
treatment and one that they cannot afford. This can be accomplished by collaboration
with other politically active APNs to change laws which would mandate the coverage of
these life saving medications, expedite their appeals to delay care, and allow for
reasonable co-pays for patients. Legislation in this area has the potential to save lives,
decrease nonadherence which can lead to disease progression, and increase access to
care.
Advanced practice nurses have the ability to obtain and allocate funds for patients
to assist with out-of-pocket costs when available through fundraising and increased
awareness of the financial obstacles that many patients face. Networking with other
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healthcare professionals, APNs have the capability to articulate the issues surrounding
this barrier to adherence in patients on oral chemotherapy and potentially increase the
amount of patient assistance funds available. Providing this information to staff who
provide direct care and may be assisting with obtaining financial assistance or dealing
with insurance companies is equally important. Nurses should be aware of changes to
insurance coverage, specifically those covered by both state and federal which many
patients have.
With more and more institutions and practices utilizing the electronic medical
records (EMR), several aspects of use will fall upon the shoulders of the APN. From
development to initiation to staff education, the APN’s role is very versatile and
important. Within the EMR, APNs can collect quality and safety data as well as assess
patient safety measures which can be utilize to assist in benchmarking against other
institutions. They can also perform audits to ensure adequate assessment and
documentation from all providers in addition to ensuring proper follow up for patients on
oral chemotherapy regimens. Additionally, APNs can be instrumental in the development
of order sets within the EMR which can make information more readily available to other
healthcare providers and in a more standardized way.
Several gaps in the research remain in regards to the many issues surrounding
nonadherence with patients on oral chemotherapy. Many of the studies found in the
literature search pertained to other patient populations or included these populations in
with oncology patients such as patients with COPD, HIV, and transplant patients. There
is a lack of research from nurses regarding the many issues surrounding adherence in
patients on oral chemotherapy. A need exists for the APN to increase the body of
knowledge that is available to other healthcare professionals by participating in research
in this area. With increased research available, recommendations for evidenced based
practice will allow nurses and providers to target their care more directly to patient needs.
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While there was not statistical evidence of various demographics affecting rates
of nonadherence, there were some studies that suggest that race, ethnicity, language, and
age all play a role in adherence. The APN working with both patients and practitioners
have the ability to assist with screening potential patients for appropriateness as well as
providing education to staff nurses who directly care for them. They also have the ability
to ensure informed consent is being obtained to maintain ethical practice and patients are
being offered choices in their care. Utilizing the APN to the greatest extent of their
certification and licensure will increase patient satisfaction, decrease admission rates and
length of stay, and decrease healthcare dollars spent. They are in a position to accomplish
this all while providing excellent and cost efficient care to the hematology/oncology
patient who often has many needs in all aspects of care. The key to managing this
complex and very ill patient population is communication between all specialties and
providers as well as interdisciplinary care to optimize patient outcomes to the greatest
extent possible.
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Appendix F
Citation of
article
1 Current
practice
patterns for
oral
chemotherap
y: results of a
national
survey. Roop
JC; Wu HS.
Oncology
Nursing
Forum. 41(2):
185-94, 2014
March 1.

Design Method

Sample

Setting

*Descriptive studythree phase study.
*Phase 1development of the
survey tool
*Phase 2- validation
of the survey tool
*Phase 3implementation and
distribution of the
survey tool.
*The final survey
consisted of 26
items- 1 addressing
consent, 7 looking
at demographic
information, 17
addressing content
areas using a Likerttype scale, and 1
free text question
for participants to
respond to.

577 oncology RNs
*96% female
*91% Caucasian
*75% worked full
time
*85% worked in the
outpatient setting
*52% had worked
greater than 15
years in oncology
*42% held a
bachelor’s degree in
nursing

*5,000 total
surveys were
delivered
electronically to a
national sample of
nurses within the
Oncology Nursing
Society
*After the initial
email, recipients
received a
reminder email 2
weeks following
*The survey was
open for a total of
10 weeks from
April- June 2012

Major
variables
within study
*Practices
pertaining to
patient care
*Nursing
resources
* Barriers to
medication
adherence

Limitations

Findings related to
nonadherence

*First use of survey
utilized, limited
validity
*Low response rate13%
*No personal
information from
RNs collected
*Lack of diversity
among respondents

*81% RN reported financial
burden greatest cause of
nonadherence
*Second greatest burden
identified- Adverse effects
(72%)
*Third greatest identifiedregimen complexity (41%)
*Only 53% of nurses
reported having policies
and procedures in place to
help manage patients on
oral chemotherapy
*56% agreed that there
were systems in place to
inform them when a patient
was placed on oral
chemotherapy to assist with
follow up and management.
*Noted in free text
comments that there is
little support for patients on
oral chemotherapy
compared with IV- “oral
patients are slipping
through the cracks”
*RNs reported issues
surrounding poor
healthcare provider
communication
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influencing
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metasummar
y and
triangulation
with
quantitative
evidence.
Johnson LA.
Clinical
Journal of
Oncology
Nursing. 19(3
Suppl): 6-30,
2015 Jun.

Qualitative metaanalysis with
quantitative
synthesis
*3 literature
searches of PubMed
and CINAHL of
qualitative studies
analyzing adherence
to oral medications.
*Studies were
excluded if they
included samples of
patients with
psychiatric illness,
substance abuse, or
taken by route
other than oral.
*Key terms
includedcompliance,
medication
adherence, oral
medication, oral
chemotherapy,
antineoplastic

Initial search yielded
26,936 articles.
*576 remained after
removal of
duplicates and
initial review
*187 remained
following secondary
review
*Final review of
inclusion and
exclusion criteria
yielded a final n of
159 full text articles

N/A

*Key terms
used in
literature
search
*Inclusion/excl
usion criteria
*Looked only
at qualitative
studies

*Included studies
with noncancer
diagnoses
*Limited evidence
in patients with
cancer as compared
with other diseases
*Nature of some of
the qualitative work
studied

*Concerns for lack of time
for education- management
became reactive instead of
proactive as a result.
*Factors associated with
either increased or
decreased adherence were
the same for both patients
with cancer and those with
other diseases
*Factors associated with
decreased adherence with
all patients: adverse effects,
forgetfulness, financial
burden or lack of insurance,
lifestyle, increased pill
burden, and regimen
complexity
*Cancer patient specific
causes of nonadherencedepression and negative
expectations of medication
efficacy
*No relationship between
age, gender, and adherence
seen
*Multiple factors that
contribute nonadherencesuggests a multifactorial
behavioral issues
surrounding nonadherence
*Recommended increased
research on patients
specific to cancer.
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3 An
intervention
to improve
adherence
and
management
of symptoms
for patients
prescribed
oral
chemotherap
y agents: and
exploratory
study.
Spoelstra SL;
Given BA;
Given CW;
Grant M;
Sikorskii A;
You M;
Decker V.
Cancer
Nursing.
36(1): 18-28,
2013 Feb.

3 group pilot studygoal was to assess
efficacy of an
Automated Voice
*Response (AVR)
system affected
adherence to oral
chemotherapy.
*Group 1 of
participants (n= 40)
received only the
AVR
*Group 2 (n=
40)received the AVR
in addition to
obtaining strategies
to increase
adherence
*Group 3 (n=39)
received AVR,
strategies to
increase adherence,
and manage their
symptom
*Study took place
over a 10 week time
span and all 119
participants
received a baseline
interview, a
symptom
management
toolkit, and an exit
interview.
*Data analyzed by

*119 Patients with
solid tumors,
greater than the age
of 21, not on
hormonal oral
agents, could
understand and
speak English, were
without hearing
defects, without
cognitive delays or
emotional and
psychological
disorders, and
owned a touchtone
phone.
*Average age- 59.6
*69% female *33%
breast cancer
patients
*54% on complex
regimens

National Cancer
institute- both
community cancer
center and
comprehensive
cancer center,
private oncology
group, and another
comprehensive
cancer center

*Symptom
Management
Toolkit
*Group 1received calls
from an
automated
voice
response(AVR)
, Group 2received calls
from an APRN
to manage
symptoms/ad
herence +
AVR, Group 3APRN +
adherence +
AVR

*Patient
characteristics not
consistent- e.g.- >
number of
Caucasian versus
other ethnicities
and > number of
females versus
males
*Only includes
patients with solid
tumors
*Participants were
asked to participate
by nurse recruiters
which limits random
sampling.

*Adherence rates similar
among all 3 groups with an
overall adherence level of
42%
*Decrease in symptom
severity in group 2 which
assisted with adverse
effects management found
slightly higher levels of
adherence- suggests
decreased symptoms may
increase adherence
*Sites adverse effects and
complex regimen as being
related to either
overadherence or
underadherence.
* Found increased number
of contacts with patients
increased adherence rates
*Found that cancer site,
drug being prescribed
(which depends on the type
of cancer), and medication
regimen were associated
with adherence levels.
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an intent to treat
analysis
4 Issues related
to
overadherenc
e to oral
chemotherap
y or targeted
agents.
Spoelstra SL;
Given BA;
Grant M;
Sikorskii A;
You M;
Decker V.
Clinical
Journal of
Oncology
Nursing.
17(7):604-9,
2013 Dec.

Longitudinal
secondary analysis
of study #3 as
described above. In
addition to above
methods, this
secondary analysis
looked more in
depth at sociodemographic
information, looked
at medical records
for evidence of
dosing changes to
oral chemotherapy,
pulled pharmacy fill
information and
compared with
records.
*Researchers
assessed
overadherence in
more detail than the
original study by
also analyzing
adherence rates
against regimen
complexity.

100 Patients with
solid tumors of the
119 within the
sample as
previously described
in article #3

Outpatient
oncology clinics at
4 sites as described
above in article #3

*Regimen
complexitycategorized
into 4 groups1) continuous
(same
medication is
taken every
day), 2)
regimens
where
patients took
medication on
days 1-14
followed by no
medications
days 15-28, 3)
patients who
were
prescribed
medication to
be taken 7
days
consecutively
followed by 7
days off, and
4) all other
dosing
regimens

*Patient
characteristics not
consistent- e.g.- >
number of
Caucasian versus
other ethnicities
and > number of
females versus
males *Only
includes patients
with solid tumors
*Did not include all
119 of the original
sample size

* 33/100 found to be
nonadherent with
treatment- 20/33 being
overadherent and 13/33
under-adherent
*Relationship was found
between regimen
complexity, cancer site, and
drug type
*Overadherence seen in
20/100 when: 1) when
starting/stopping drug and
2) when pharmacies
delivered medications prior
to start of cycle
*Patients with breast
cancer were found to have
greater rates of
overadherence as
compared with other sites
of cancer
*As regimen complexity
increased, as did levels of
overadherence
*Of the 52 patients with a
simple regimen
(continuous), only 1 patient
was found to be
overadherent.
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5 Perceptions
and
experiences
of patients
receiving oral
chemotherap
y.
Simchowitz,
B; Shiman L;
Spencer J;
Brouillard D;
Gross A;
Connor M;
Weingart SN.
Clinical
Journal of
Oncology
Nursing,Aug
2010; 14(4):
447-453.

*Patient and
caregiver survey
and focus group
*Two 2 hour focus
groups- patients
were described the
study and allowed
time for questions
prior to researchers
obtaining consent.
*Initial survey of
participants
collected sociodemographic
information
*During the
sessions, 1
researcher
facilitated with
probing questions
while another 2
researchers
observed and took
notes.
*Sessions were
auto-recorded and
transcribed
*Transcripts of the
interviews as well as
notes taken during
the sessions were
analyzed and
grouped into major
and minor themes

*15 past and
present oral chemo
patients and caregivers- 73% were
female, 93% were
Caucasian, mean
age- 56 years old.
73% had private
insurance, 13% had
Medicaid, while 7%
were covered by
Medicare. Only 1 of
the fifteen
participants were
not currently being
prescribed oral
chemotherapy at
the time of the
study. Patients were
on oral therapies for
an average of 22
months.

*Dana Farber/
Harvard Cancer
Center in Boston,
MA

*Sociodemographic
information
*Two 2 hour
focus groups
led by a
member of the
study group.
*Sessions had
open format
so information
between the
two groups
varied.
*Oral
chemotherapy
prescribed
(sunitinib,
capecitabine,
mercaptopurin
e,
temzolomide,
lapatinib, and
imatinib)

*Selection biasParticipants were
identified by their
oncologist- may
have been more
motivated and
knowledgeable than
most patients
*Assessed
adherence based on
self-report; may
have skewed results
*Participants only
from one
comprehensive
cancer center
*No data collected
on disease type

*Many participants were
unprepared to manage the
adverse effects of their oral
chemotherapy
*Described few issues
around adherence- believe
due to embarrassment
related to admitting their
own errors
*Cited financial burden as
an issue as well as finding
pharmacies that carried the
drug as they are not
stocked at retail pharmacies
*Patients identified a need
for improved patient
education surrounding the
use of oral chemotherapies
(including adverse effects as
well as handling of the
drugs)
*Participants felt that more
frequent follow up with
their providers would have
been beneficial

67

6 Feasibility
Pilot on
Medication
Adherence
and
Knowledge in
Ambulatory
Patients With
Gastrointestin
al Cancer.
Sommers,
Robin M.;
Miller,
Kathleen;
Berry, Donna
L.: Oncology
Nursing
Forum, Jul
2012.
39(4)373-9.

Descriptive study,
feasibility pilot
study
*Study team
included physicians,
clinic nurses, NPs,
and research
nurses- all of whom
received training on
screening for
eligible patients and
data collection.
*Participants were
given written dosing
instructions and
education material
on their new oral
chemotherapies.
They were also
given a drug diary
with instructions,
including to be bring
diary back to first
appointment
following
completion of their
first cycle
*72 hours after
initiation of the
study, patients were
contacted to assess
understanding of
their medication
*Following
completion of the

30 patients with GI
cancer on 1+ oral
chemotherapy
*Convenience
sample
*Participants were
>18 years old, could
read and write
English, and had
access to a
telephone
*23 participants
were male, 7 were
female
*Mean age – 53
years

Outpatient
oncology unit at
the National
Cancer Institute
*Located within an
urban community
in the northeastern
US

*GI cancer
patients only
*Written and
verbal
education
*Telephone
contacts
*Patient
knowledge
*Drug diary
*Self-reporting
of medication
adherence
among
patients

*Convenience
sample- may not be
representative of
majority patient
population
*Able to read and
write *English
speaking only
*Those with
telephone access
*Only enrolled for
first cycle- 3-4
weeks, may have
altered results
based on short time
span
*Possible
Hawthorne Effect
from self-reporting

*17 participants
experienced adverse effects
within 72 hours- 8 of whom
unable to verbalize
management of symptoms
*7 had chemotherapy held
due to medication toxicities
*Most (n= 21) were able to
verbalize 1-3 symptoms of
chemo, but few were able
to verbalize drug-specific
adverse effects to report
*23 patients verbalized
increased satisfaction with
72 hour follow up call to
assess understanding of
information and provide
clarification
*MMAS-8 scores ranged
among the 30 participants
from 5-8 (higher the score,
the higher the level of
adherence)
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7 Evaluation of
an education
program to
facilitate
patient
adherence,
toxicity
monitoring,
and promote
safety and
wellbeing in
the selfadministratio
n of oral
chemotherap
y in the home
setting: an
Australian
study.
Griffiths, Tina:
Pascoe,
Elizabeth;

first cycle, nurses
reviewed their drug
diary with patients
as well as having
patients complete
the Morisky
Medication
Adherence Scale
(MMAS-8)
questionnaire, both
of which were used
to assess adherence
to their medication.
Two-stage, mixed
method approach
to evaluate a
patient education
program collecting
qualitative and
quantitative data
*Time 1- Education
provided to patientadapted MASCC
evaluation
questionnaire (total
of 13 questions)
filled out by
patients
immediately before
and following
education being
provided
*Patients also asked
to fill out the
National

15
hematology/oncolo
gy patients
*Greater than the
age of 18 without
formal exclusion
criteria
*Participants were
obtained via
referrals from their
medical oncologists
*Patients with
limited English were
accompanied by
either an
interpreter or a
family member who
was proficient in
English
*Participants were
male with a mean
age of 55.75 years,

Nurse led
outpatient clinic
during December
2012 to March 213

*Cancer
diagnoses
*Specific oral
chemotherapy
*Education
session and
post education
program
*NCCN
Distress
Thermometer
Screening Tool

*No formal
exclusion criteria
*Small sample size
limit ability to
generalize to other
populations
*Limited time
frame- short time
span not
representative of
how patients
manage their
chemotherapy over
a prolonged period
of time.
*Those participants
with limited Englishnot all accompanied
by a trained
interpreter.

*Lack of or limited patient
education regarding PO
chemotherapy plays heavily
in patient adherence
*Education with complex
regimens increased
adherence
*100% reported improved
understanding following the
education program.
*Distress Thermometer
level decreased from initial
interaction following
education to follow up the
next week from 3.8/10
down to 2.3/10
*All patients within the
study reported the written
take home materials to be
the most beneficial in
conjunction with the verbal
reinforcement.
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Australian
Journal of
Cancer
Nursing. Nov
2014; 15(2):
30-38.

Comprehensive
Cancer Network
(NCCN) Distress
Thermometer
Screening Tool to
assess patients
potential stress
levels.
*Patients given
written instructions
which includeddrug specific
information,
adverse effects,
food and drug
interactions, when
to contact their
provider, and
special precautions
associated with
their medications.
*Time 2- Took place
1 week following
education session.
Assessment of
efficacy of initial
session conducted
via telephone call
from nurse. NCCN
Distress
Thermometer
Screening Tool
completed and
additional support
provided to patient

7 were female with
a mean age of
58.28.

*Participants reported they
felt that the increased
education assisted with
increased adherence as
they knew better how to
manage their adverse
effects, when to take their
medications, and when to
call their providers.
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as needed by nurse.

8 Current
nursing
practice for
patients on
oral
chemotherap
y: a
multicenter
survey in
Japan.
Komatsu H;
Yagasaki K;
Yoshimura
K.BMC
Research
Notes. 2014
Apr 23: Vol. 7,
pp 529.

Two self- reported
surveys were
distributed to 309
cancer centers and
141 large hospitals
in Japan.
*The first survey
was directed
towards nurseassessed staffing,
nursing
demographics and
experience and was
40 questions.
*The second survey
was patient based
including 10
additional
questions. Assessed
information on
patient
demographics and
adherence.
*Multivariate
logistic regression
was utilized to
identify elements
surrounding
adherence related
practices in nursing.

62 RNs from 62
hospitals were
consented to
participate in both
surveys including
the patient based
which looked at 249
patients on oral
chemotherapy
*Average age of
participants- 41.5
years
*Average nursing 19.4, and
chemotherapy
experience 11.6
years.
*72.6% were
oncology nurse
certified.

Designated cancer
centers and large
general hospitals in
Japan

*Utilized both
cancer centers
and hospital
based
ambulatory
cancer centers
*Size of
facilities which
participated

*Patient based
survey answered by
RNs not patients
*Looks only at
nursing practices
related to
adherence

*Nursing practices
surrounding oral chemo
varied greatly around the
country
*Few offered system
specific needs/education
*Increased adherence
found related to RN
background, treatment
type, and healthcare system
related factors
*RNs found rarely to inquire
how patients understood
therapy, how they managed
their meds at home, or level
of confidence of
administration
*Only 64.5% of patients
reported understanding of
their medication schedules
and 58.1% of their
medications
*20% of nurses were
unclear as to their role in
monitoring and educating
patients on oral
chemotherapy, 30.6%
assessed patient confidence
in taking their medications.
*Nurses were less likely to
ask questions related to
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patient adherence of
patients who were refilling
their medications as
compared with those being
given new prescriptions.
9 Putting
Evidence Into
Practice:
EvidenceBased
Interventions
for Oral
Agents for
Cancer.
Spoelstra,
Sandra L.;
Sansoucie,
Holly: Clinical
Journal of
Oncology
Nursing, June
2015: 19(3):
60-72.

Systematic review
*Search of PubMed
and CINAHL
*Search termsmedication
adherence, patient
compliance, oral
chemotherapy, antineoplastic,
nonadherence
*Study types
included systematic
reviews, practice
guidelines, metaanalyses, and
clinical research
*Interventions were
broken up into
levels of evidence:
“recommended for
practice”, “likely to
be effective”,
“effectiveness not
found”, “benefits
balanced with
harms” and “not
recommended for
practice”

131 studies
*Initial search
yielded 25,478
articles, after
utilizing inclusion
and exclusion
criteria and removal
of duplicates, a total
of 131 articles were
utilized for the
study.

N/A

*Interventions
to increase
adherence

*Included in their
study, articles of
patients outside of
hematology/oncolo
gy population
*Primarily
intervention based
*Small sample sizes
of several studies
examined

*Majority of research was
found in noncancerous
conditions- found a need
for further research
*Lack of patient education
and feedback greatly
contribute to nonadherence
*Adverse effects limited
adherence
*High rate of depression in
patients with chronic
disease can affect
adherence
*Found the highest number
of studies to support multicomponent interventionsi.e.- a combination of
interventions to increase
adherence, shown to
significantly increase
adherence to oral
chemotherapy
*Most interventions that
addressed adherence were
targeting management of
adverse effects- not
education to decrease or
prevent them
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1 Adherence
0 enhancing
interventions
for oral
anticancer
agents: a
systematic
review.
Mathes, Tim;
Antoine,
Sunya-Lee;
Pieper, David;
Eikermann,
Michaela;
Cancer
Treatment
Reviews, Feb
2014; 40(1):
102-108.

Systematic review
*Search conducted
in Medline and
Embase
*Inclusion criteriaPatients with
diagnosis of cancer,
tanking oral
chemotherapy, >16
years old, assessed
adherence, either in
German or English,
controlled studies,
interventions to
increase adherence
*Quality of studies
were assessed via
National Institute
for Health Clinical
Excellence (NICE)
tool for cohort
studies, for
randomized control
trials (RCT) the
Cochrane Effective
Practice and
Organization of Care
Group tool was
utilized.

Initial search yielded
2309 articles
*After application of
inclusion criteria
and removal of
duplicates, a total of
6 articles were
utilized for the
study

N/A

*Barriers to
adherence to
oral
chemotherapy
*Monitoring
patients for
adherence

*Limited sample
size
*Low
methodological
study quality- most
rated moderate to
low on study quality
*Did not limit
publication date

*“Likely to be effective” in
increasing adherence- text
messages, automated voice
response, and treatment of
depression
*Education main barrier
assessed with interventions
*Forgetfulness- several
studies looked at reminders
for patients
*Found that interventions
focusing on education were
most advantageous in
decreasing nonadherence
as it addresses several
causes of poor adherence
of oral chemotherapy.
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1 Essentials for
1 Oral
Oncolytics:
Developing a
Nursing
Reference.
Matthews,
Jennifer;
Caprera,
Patricia
Holland;
Clinical
Journal of
Oncology
Nursing, Oct
2014; 18(5):
E88-92.

17 educational inservice programs for
oncology staff
between September
2011 and February
2013.
*Roundtable
discussion groups
were conducted
prior to the inservice assessing
the challenges of
maintaining
adherence in
patients on oral
chemotherapy
*Participants were
surveyed of their
policies and
procedures for
education of
patients prescribed
oral chemotherapy,
what resources
were available for
education, and their
confidence level in
their ability to
provide education
to patients.
*Participants were
also surveyed on
their standards for
documentation,
what type of

200 RNs, APRNs,
pharmacy industry
consultants, and
pharmacists

Inpatient and
outpatient facilities
across the US
including major
cancer centers in
Boston, MA, freestanding
hematology/oncol
ogy offices, private
offices, hospital
affiliated cancer
centers, inpatient
oncology units,
and cancer centers
with several
different clinical
sites.

*Position of
staff involved
in educational
in-service

*Poor
documentation of
methodology
techniques

*Education from staff to
patients varies heavilyoften lacking
*Poor education attributed
to time constraints for
teaching and follow up from
clinicians as well as limited
experience with the drugs
being given
*Lack of or decreased
follow up with patient for
assessment
*Lack of individualization of
plan of care for patients
including drug specific
adverse effects, laboratory
monitoring, and toxicity
monitoring lead to poor
patient outcomes and
decreased adherence.
*Participants felt that lack
of time limited ability to
assess patient’s
understanding of their
medications, time to
answer questions, and
assess risk for poor
adherence in many patients
leading to poor patient
outcomes and adherence.
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1 The role of
2 the nurse in
patient
education
and follow up
of people
receiving oral
anti-cancer
treatment: an
Australian
survey.
Johnson,
Catherine;
Adler, Kim;
Australian
Journal of
Cancer
Nursing. Jun
2014; 15(1):
4-12.

charting system
they utilized, and
follow up with
patients to monitor
oral adherence.
Cross- sectional
survey
*Invitation to
participate in the
study were
distributed
nationwide via
email to members
of the Cancer
Nurses Society of
Australia (CNSA)
*Survey consisted of
a 20 multiple choice
and open ended
questionnaire
*A follow up email
was sent to follow
up two weeks
following the initial
email invitation.
*Results of the
survey were
compared with the
Multinational
Association for
Supportive Care in
Cancer (MASCC)
survey which was
performed in 2006.

182 survey
responses from RNs
who were members
of Cancer Nurses
Society of Australia
*Participants were
anonymous
*Researchers did
not have direct
access to
participants.
*Most participants
reports > 16 years
experience in
oncology nursing
*28% were bachelor
prepared
*21% were
oncology certified

Email surveys of
RNs across
Australia

*Role of RN in
patient
education
*Follow up of
patients taking
oral
chemotherapy

*Low % of
responses of RNs
*Snowball sampling

*30% reported lack of time
for education
*RN education of oral
chemotherapy lacking
*20% reported difficulty
with safety issues and 29%
related to adverse effect
management
*RN respondents
suggested need for formal
education to patients and
protocols on follow up to
increase adherence
*All respondents reported
working with on average 7
of the 22 oral
chemotherapy drugs in the
survey as well as
investigational and research
medications. Indicates a
potential lack of education
regarding a majority of
other medications that
patients may be prescribed.
It also indicates the rapid
evolution of medication
available to patients that
staff need to be aware of.
*Staff who worked in the
inpatient setting reported
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lack of education regarding
oral chemotherapy agents
*When compared with the
MASCC survey, there was a
great increase over the
seven year span in the
education and follow
directed to patients on oral
chemotherapy.
Additionally, 39% of nurses
reported that patient
education was provided by
prescribing physicians
which was double the rate
from the MASCC survey.
*20% of nurses reported
not having enough time to
provide education, 30%
reported a knowledge
deficit regarding oral
chemotherapy agents.
*The number of nurses who
reported policies and
guidelines in place for the
management of oral agents
only increased slightly from
the MASCC survey from
64.5% to 71% despite the
increasing use of these
medications
*Nurses requested
formalized education on
oral therapies similar to
those of intravenous
chemotherapy.
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1 Treatment
3 With Oral
Anticancer
Agents:
Symptom
Severity and
Attribution,
and
Interference
With
Comorbid
Management.
Spoelstra,
Sandra L;
Given,
Charles W;
Sikorskii, Alla;
Majumder,
Atreyee;
Schueller,
Monica;
Given,
Barbara A;
Oncology
Nursing
Forum. Jan
2015; 42(1):
80-88.

Descriptive
exploratory study to
assess the severity
and occurrence of
adverse effects in
affecting the
adherence rates of
patients being
prescribed oral
chemotherapies.
*Conducted over an
8 week time span
*Total of five
telephone
interviews were
conducted on
patients being
prescribed oral
therapies
*Data was entered
in the PROMIS
Assessment Center
Data Collection
Platform
*At each interview
symptoms were
assessed utilizing
the Symptom
Experience
Inventory. If
symptoms were
reported, they were
asked to rate them
on a scale to 1-10
with 10 being the

34 patients were
initially approached
for participation in
the study as a
convenience sample
*3 reported not
being interested
and another did not
have the time to
participate
*A total of 30 adult
patients consented
*Only 28 completed
all five telephone
interviews.
*Mean age- 65.1
years
*Most site of
cancer- colorectal
(n= 10)
*21 had late stage
cancer

1 comprehensive
cancer center and
2 community
based oncology
programs in the US

*Symptoms
*Comorbid
conditions

*Utilized
convenience sample
*Self-reporting of
adherence
*Small sample size

*Most patients reported
that they at least 2
comorbid conditions
increased effects from oral
chemotherapy
*Most patients included
had complex regimens
which often included IV
chemotherapy- regimen
complexity found to have
no statistical significance.
*Of the 23 patients with
comorbid conditions, all
reported that the
management of their
cancer interfered with their
ability to manage their
comorbidities.
*Fatigue was the most
common adverse effect
reported by patients. Other
symptoms commonly
reported >50% of
interviews included
numbness and tingling and
sleep disturbances. 33% of
patients reported- diarrhea,
pain, swelling of the
extremities, poor appetite,
rashes, and shortness of
breath. Patients expressed
that symptoms affected
their ability to take their
medications often.
*27 patients reported being
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worst.
*Adherence rates
were assessed via
self-report as a yes
or no at each
interview.

1 Determinants
4 and
associated
factors
influencing
medication
adherence
and
persistence to
oral
anticancer
drugs: A
systematic

Systematic review
*Literature search
conducted in
PubMed, Cochrane
database, Web of
Science, and CINAHL
*Inclusion criterialooked only at oral
chemotherapy,
assessed factors
related to
adherence or
compliance of oral

*Original search of
the literature
yielded 3,351
articles
*After elimination
of duplicates, and
consideration of
inclusion and
exclusion criteria25 articles were
utilized for the
study

N/A

*Search
engines
selected
*Quality of
research
obtained

*Most patients
within studies found
were breast cancer
patients- may not
be generalize to
other populations
*Scarce findings
with other oncology
populationsrequires additional
research
*Potential conflict
of interest with

adherent 100% of the time.
Of the three who reported
nonadherence- one stated
that she stopped her
medication for 3 weeks for
vacation as she did not wish
to experience adverse
effects, one was due to the
fact that her medication
had not come in the mail,
and the third did not
provide a reason to
researchers.
*Researchers felt that
results of treatment
provided strong evidence to
support that increased rates
of adverse effects
interfered with patient’s
ability to manage their oral
chemotherapies and
decreased adherence.
*Treatment related side
effects were most
frequently reported reason
for non-adherence
*Longer duration of
treatment also led to
decreased adherence rates
*Most common reason for
unintentional
noncompliance: forgetting a
dose; most common reason
for intentional: decreased
perceived efficacy of
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review.
Verbrugghe,
M;
Verhaeghe, S;
Lauwaert, K;
Beeckman, D;
Van Hecke, A:
Cancer
Treatment
Reviews, Oct
2013; 39(6):
610-621.

therapies, subjects
>18 years old,
research with either
a strong or
moderate
methodological
quality
*Search terms
included:
medication
adherence, patient
compliance,
antineoplastic
agents, neoplasms,
tumor, cancer,
patient adherence
*Searched material
from between 19902012 in either
English, German, or
Dutch
*Excluded research
conducted in
developing
countries as the
healthcare systems
are so greatly
different from
developed.
*Methodological
quality was
reviewed
independently by
two reviewers while
utilizing the Quality

some studies as
were performed by
commercial or
pharmaceutical
grants
*Wide variation
noted among the
definitions of
adherence- varied
from <80% to
<100% for
nonadherence,
>110% for
overadherence.

treatment, or no added
benefit from medication
*Lack of follow up
appointments and short
visit times
*Poor patient and family
education
*Socioeconomic statusCopay of ≥$30 can be
barrier to obtaining
medication
*Mixed results in how
presence of polypharmacy
as well as comorbidities
affect adherence. Some
studies have shown these
increase adherence while
others have shown the
opposite.
*Age ≤45 and ≥85 were
found to have increased risk
for nonadherence (n= 9)
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1 Exploring
5 chronic
myeloid
leukemia
patients’'
reasons for
not adhering
to the oral
anticancer
drug imatinib
as prescribed.
Eliasson, L;
Clifford S;
Barber N;
Marin D;
Leukemia
Research.
May 2011;
Vol. 35(5),
626-30.

Assessment Tool for
quantitative studies,
the Critical
Appraisal Skills
Programme (CASP)
which looked at
quantitative studies.
Qualitative study
*Researchers
outfitted patient’s
medication bottles
with an electronic
device that
monitored the date
and time each time
the bottle was
opened and closed.
*Measurement
occurred over a 3
month period.
*Researchers
defined
nonadherence as
adherence rate
≤90%. This rate was
chosen based on
common adherence
rate from similar
studies.
*Adherence was
also assessed via
self-reporting
*Interviews were
recorded and
transcribed then

21 Chronic Myeloid
Leukemia (CML)
patients on imatinib
for ≥2 years.

Outpatient CML
clinics located in a
teaching hospital
in the United
Kingdom

*Self report of
adherence
*Participants
recruited from
previous
related studyselected 4
nonadherent
patients for
every one
adherent

*Looked only at
patients on imatinib
with CML- may not
be generalized to
other oncology
populations
*Self-report of
adherence- possible
Hawthorne Effect
*Some funding was
obtained by
researchers from
Novartis
*2 researchers
declared affiliation
with Novartis
and/or Bristol
Myers Squibb

*Unintentional causes
included: forgetfulness
(n=13), could not obtain
medication from pharmacy
(n=1), and unintentional
overdosing
*Intentional nonadherence
(n=10)- Most commonly
reported was adverse
effects of treatmentnausea, fatigue.
*12:21 were not aware of
the clinical consequences of
missing a dose and did not
feel this would affect their
clinical response to
treatment
*A total of 14% of
participants were
nonadherent.
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analyzed via
quantitative data
analysis software.
Meta-categories
were identified
from transcripts.
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Appendix G
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
*Numbers in evaluation correspond with those assigned to articles in data extrapolation chart*

Questions

Evaluation
Summary Topic
1. Is the summary specific in scope and
Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
application?
15
Not completelyNoSummary Methods

2. Is the authorship of the summary
transparent?

3.

4.

5.

6.

7.

8.

9.

10.

Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15
Not completelyNoAre the reviewer(s)/editor(s) of the
Yes- 1, 2, 3, 4, 5, 7, 9, 10, 11, 14, 15
summary transparent?
Not completely- 6, 8, 12, 13
No- 7
Are the research methods transparent
Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
and comprehensive?
15
Not completelyNoIs the evidence grading system
Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15
transparent and translatable?
Not completely- 12
NoSummary Content
Are the recommendations clear?
Yes- 1, 2, 3, 4, 6, 7, 8, 9, 11, 12, 13, 14
Not completely- 5, 10
No- 15
Are the recommendations
Yes- 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 14
appropriately cited?
Not completely- 8, 10
No- 15
Are the recommendations current?
Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15
Not completelyNoIs the summary unbiased?
Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15
Not completelyNoSummary Application
Can this summary be applied to your
Yes- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
patient(s)?
15
Not completelyNo-

